We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » After Five Failures, Lilly’s Solanezumab is Hoping for a Win in Alzheimer’s Research
After Five Failures, Lilly’s Solanezumab is Hoping for a Win in Alzheimer’s Research
Eli Lilly’s solanezumab, an investigational antibody treatment for Alzheimer’s disease, has been floundering between outright disasters and glimpses of hope since the mid-2000s. It has disappointed in five separate phase 3 studies so far, most recently last year when it flopped in the highly anticipated DIAN-TU study, which found that it exerted no cognitive benefit in patients with dominantly inherited Alzheimer’s disease.